Journal of Korean Medical Science

Korean Acad Medical Sciences (대한의학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib

  • Kim, Myung Soo (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Chung, Ho Seok (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Hwang, Eu Chang (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Jung, Seung Il (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Kwon, Dong Deuk (Department of Urology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Hwang, Jun Eul (Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Bae, Woo Kyun (Department of Hemato-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School) ;
  • Park, Jae Young (Department of Urology, Korea University Ansan Hospital) ;
  • Jeong, Chang Wook (Department of Urology, Seoul National University Hospital) ;
  • Kwak, Cheol (Department of Urology, Seoul National University Hospital) ;
  • Song, Cheryn (Department of Urology, Asan Medical Center) ;
  • Seo, Seong Il (Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Byun, Seok-Soo (Department of Urology, Seoul National University Bundang Hospital) ;
  • Hong, Sung-Hoo (Department of Urology, The Catholic University of Korea, Seoul St. Mary's Hospital) ;
  • Chung, Jinsoo (Department of Urology, National Cancer Center)
  • Received : 2018.06.02
  • Accepted : 2018.08.27
  • Published : 2018.12.17
⟨ Previous Next ⟩

Abstract

Background: To evaluate survival outcomes and prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who received sunitinib (SU) and pazopanib (PZ) as first-line therapy in real-world Korean clinical practice. Methods: Data of 554 patients with mRCC who received SU or PZ at eight institutions between 2012 and 2016 were retrospectively reviewed. Based on the targeted therapy, the patients were divided into SU (n = 293) or PZ (n = 261) groups, and the clinicopathological variables and survival rates of the two groups were compared. A multivariable Cox proportional hazard model was used to determine the prognostic factors for OS. Results: The median follow-up was 16.4 months (interquartile range, 8.3-31.3). Patients in the PZ group were older, and no significant difference was observed in the performance status (PS) between the two groups. In the SU group, the dose reduction rate was higher and the incidence of grade 3 toxicity was more frequent. The objective response rates were comparable between the two groups (SU, 32.1% vs. PZ, 36.4%). OS did not differ significantly between the two groups (SU, 36.5 months vs. PZ, 40.2 months; log-rank, P = 0.955). Body mass index, Eastern Cooperative Oncology Group PS > 2, synchronous metastasis, poor Heng risk criteria, and liver and bone metastases were associated with a shorter OS. Conclusion: Our real-world data of Korean patients with mRCC suggested that SU and PZ had similar efficacies as first-line therapy for mRCC. However, PZ was better tolerated than SU in Korean patients.

Keywords

Acknowledgement

Supported by : Chonnam National University Hwasun Hospital

References

  1. Leibovich BC, Lohse CM, Crispen PL, Boorjian SA, Thompson RH, Blute ML, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010;183(4):1309-15. https://doi.org/10.1016/j.juro.2009.12.035
  2. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ. Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89(3):604-14. https://doi.org/10.1002/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q
  3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30(4):843-52. https://doi.org/10.1016/S0094-0143(03)00056-9
  4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 2006;98(18):1331-4. https://doi.org/10.1093/jnci/djj362
  5. Randall JM, Millard F, Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev 2014;33(4):1109-24. https://doi.org/10.1007/s10555-014-9533-1
  6. Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, et al. Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017;15(6):804-34. https://doi.org/10.6004/jnccn.2017.0100
  7. Ljungberg B, Albiges L, Bensalah K, Bex A, Giles RH, Hora M, et al. EAU guidelines on renal cell carcinoma. http://uroweb.org/guideline/renal-cell-carcinoma. Updated 2017. Accessed May 10, 2017.
  8. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31. https://doi.org/10.1056/NEJMoa1303989
  9. Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014;370(18):1769-70. https://doi.org/10.1056/NEJMc1400731
  10. Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, et al. Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER-medicare database analysis. Clin Genitourin Cancer 2017;15(4):e573-82. https://doi.org/10.1016/j.clgc.2016.12.005
  11. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 2014;32(14):1412-8. https://doi.org/10.1200/JCO.2013.50.8267
  12. Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer 2016;65:102-8. https://doi.org/10.1016/j.ejca.2016.06.016
  13. Motzer RJ, Escudier B, Bukowski R, Rini BI, Hutson TE, Barrios CH, et al. Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer 2013;108(12):2470-7. https://doi.org/10.1038/bjc.2013.236
  14. Kim HS, Hong MH, Kim K, Shin SJ, Ahn JB, Jeung HC, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology 2011;80(5-6):395-405. https://doi.org/10.1159/000330361
  15. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009;15(7):2497-506. https://doi.org/10.1158/1078-0432.CCR-08-1893
  16. Lalani AA, Li H, Heng DY, Wood L, Kalirai A, Bjarnason GA, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience. Can Urol Assoc J 2017;11(3-4):112-7.
  17. Pan X, Huang H, Huang Y, Liu B, Cui X, Gan S, et al. Sunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma. Urol Oncol 2015;33(6):268.e9-268.e15. https://doi.org/10.1016/j.urolonc.2015.03.008
  18. Lee JL, Kim MK, Park I, Ahn JH, Lee DH, Ryoo HM, et al. RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial. Ann Oncol 2015;26(11):2300-5. https://doi.org/10.1093/annonc/mdv357
  19. Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, et al. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. Urol Oncol 2017;35(9):541.e7-541.e13. https://doi.org/10.1016/j.urolonc.2017.05.007
  20. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol 2014;191(3):611-8. https://doi.org/10.1016/j.juro.2013.08.090
  21. Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R. Feasibility, safety, and efficacy of an alternative schedule of sunitinib for the treatment of patients with metastatic renal cell carcinoma: a retrospective study. Drugs R D 2017;17(4):585-96. https://doi.org/10.1007/s40268-017-0209-5
  22. Mittal K, Derosa L, Albiges L, Wood L, Elson P, Gilligan T, et al. Drug holiday in metastatic renal-cell carcinoma patients treated with vascular endothelial growth factor receptor inhibitors. Clin Genitourin Cancer 2018;16(3):e663-7. https://doi.org/10.1016/j.clgc.2017.12.014
  23. Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol 2016;34(30):3655-63. https://doi.org/10.1200/JCO.2016.66.7311
  24. McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol 2014;65(3):577-84. https://doi.org/10.1016/j.eururo.2013.08.012
  25. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 2017;15(3):363-70. https://doi.org/10.1016/j.clgc.2017.01.010
  26. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2(8):584-93. https://doi.org/10.1038/nrc867
  27. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883-92. https://doi.org/10.1056/NEJMoa1113205

Cited by

  1. Custo-efetividade do pazopanibe comparado ao sunitinibe para câncer renal metastático na perspectiva de um hospital do Sistema Único de Saúde vol.35, pp.8, 2018, https://doi.org/10.1590/0102-311x00108218
  2. Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Me vol.11, pp.12, 2018, https://doi.org/10.3390/cancers11121830
  3. First-Line Pazopanib Treatment in Metastatic Renal Cell Carcinoma: Real-World Data From a Single Chinese Center vol.11, pp.None, 2018, https://doi.org/10.3389/fphar.2020.517672
  4. Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer vol.26, pp.4, 2020, https://doi.org/10.1007/s12253-020-00853-9
  5. Outcomes of starting low-dose pazopanib in patients with metastatic renal cell carcinoma who do not meet eligibility criteria for clinical trials vol.32, pp.3, 2018, https://doi.org/10.4103/uros.uros_145_20